Trial Profile
Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Brain cancer; Solid tumours
- Focus Adverse reactions
- 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov
- 29 Nov 2007 The expected completion date for this trial is now 1 Oct 2008 according to ClinicalTrials.gov.